The role of inflammation in the immune evasion of KRas.

Abstract excerpt

KRas, NRas and HRas mutations are recognized in over 25% of all tumors, with the predominant mutations occurring at amino acids G12 or G13. While small molecule inhibitors of KRas show therapeutic promise, KRas has largely resisted control by immunotherapy in clinical cases, although immune responses may be detected following vaccination. Inflammation is a recognized precursor of most KRas-associated tumors. In...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cathepsin B
• Share to Immune Evasion
• Share to Inflammation